Desmoid tumor differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
Line 198: | Line 198: | ||
* t(7;16) (q34:p11) | * t(7;16) (q34:p11) | ||
Fusion gene: | Fusion gene: | ||
* FUS/CREB3 L2 | * FUS/CREB3 L2 (76%-96%) | ||
* FUS/CREB3 L1 (4%-6%) | |||
| | | | ||
* Low to moderate cellularity | * Low to moderate cellularity | ||
Line 230: | Line 231: | ||
* High metastasizing potential/local aggressive infiltration | * High metastasizing potential/local aggressive infiltration | ||
* High local recurrence | * High local recurrence | ||
| | |_ | ||
* | * | ||
|Majority occurring in subfascial location and rarely involving subcutis or dermis in following sites: | |Majority occurring in subfascial location and rarely involving subcutis or dermis in following sites: | ||
Line 242: | Line 243: | ||
* Maxillofacial region (rarely) | * Maxillofacial region (rarely) | ||
| | | | ||
* Painless, slow-growing well-circumscribed mass | |||
* Average size-5cm (ranges from 1-20cm) | |||
| | | | ||
|- | |- | ||
|'''Solitary fibrous tumor''' | |'''Solitary fibrous tumor''' | ||
|Intra-chromosomal inversion at: | |||
* Chromosome 12q13 leading to formation of ''NAB2–STAT6'' chimeric fusion gene (highly variable breakpoints) | |||
''TERT'' promoter mutations responsible for: | |||
* High aggressive potential | |||
* Metastatic potential | |||
| | | | ||
* Fibroblast-like tumor cells arranged in a “patternless” pattern | |||
* Collagenous stroma with staghorn, hyalinized blood vessels | |||
* Increased mitotic activity | |||
* Hypercellularity | |||
* Nuclear atypia | |||
* Pleomorphism | |||
* Lipomatous, myxoid, or dedifferentiated variants | |||
|Positive for: | |Positive for: | ||
* CD34 | * CD34 | ||
* Vimentin | |||
In few cases, positive for: | |||
* Focal keratin reactivity | |||
* Focal desmin reactivity | |||
Negative for: | |||
* CD31 | |||
* Cytokeratin | |||
* Glial fibrillary acidic protein | |||
| | | | ||
* Metastasis(10%-20%) | |||
* Recurrence (10%-20%) | |||
| | | | ||
| | | | ||
* Any anatomic site | |||
| | | | ||
| | | |
Revision as of 15:19, 7 March 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Faizan Sheraz, M.D. [3]
Overview
Desmoid tumor must be differentiated from acute hematoma, lymphoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma, leiomyosarcoma, neurofibroma, benign fibrous tumor and primitive neuroectodermal tumor.
Differentiating Desmoid tumor from other Diseases
- Extra-abdominal fibromatosis/desmoid tumor must be differentiated from:[1][2][3]
- Fibrosarcoma/fibroblastic sarcoma
- Low-grade fibromyxoid sarcoma[4][5]
- Gardner fibroma[6]
- Intra-abdominal fibromatosis must be differentiated from:[7]
- Gastrointestinal stromal tumor (GIST)
- Solitary fibrous tumor (SFT)
- Inflammatory myofibroblastic tumor (IMT)
- Sclerosing mesenteritis
- Retroperitoneal fibrosis due to:[8]
- Idiopathic [Ormond's disease]
- Secondary to certain drugs
- Underlying malignancy such as lymphoma
- Furthermore, desmoid tumors must be differentiated from:
Disease entity | Etiology (Genetic or others) | Histopathological findings | Immunohistochemical staining | Benign/Malignant | Risk factors | Common site of involvement | Clinical manifestations | Other associated findings |
---|---|---|---|---|---|---|---|---|
Desmoid tumor | Sporadic desmoids are associated with following mutations:
Familial desmoids/Hereditary desmoid disease is associated with:
Pediatric desmoids have following additional mutations involving:
|
Histologically, desmoid tumors consist of:
|
Positive for:
Negative for:
Positive antibodies for:
|
|
|
|
|
Desmoids may be associated with following:
|
Fibrosarcoma/Fibroblastic sarcoma |
|
|
Strongly positive for:
Negative for:
|
|
|
Primary bone malignancy involving end of long bones:
|
|
|
Low-grade fibromyxoid sarcoma[4][5][9][10][11][12][13][14] | Translocation:
Fusion gene:
|
|
Positive for:
Occasionally positive for:
Negative for:
|
|
_
|
Majority occurring in subfascial location and rarely involving subcutis or dermis in following sites:
|
|
|
Solitary fibrous tumor | Intra-chromosomal inversion at:
TERT promoter mutations responsible for:
|
|
Positive for:
In few cases, positive for:
Negative for:
|
|
|
|||
Neurofibroma | Positive for:
|
Reference
- ↑ Economou, Athanasios; Pitta, Xanthi; Andreadis, Efstathios; Papapavlou, Leonidas; Chrissidis, Thomas (2011). "Desmoid tumor of the abdominal wall: a case report". Journal of Medical Case Reports. 5 (1): 326. doi:10.1186/1752-1947-5-326. ISSN 1752-1947.
- ↑ Kasper B, Ströbel P, Hohenberger P (2011). "Desmoid tumors: clinical features and treatment options for advanced disease". Oncologist. 16 (5): 682–93. doi:10.1634/theoncologist.2010-0281. PMC 3228186. PMID 21478276.
- ↑ Carlson JW, Fletcher CD (2007). "Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature". Histopathology. 51 (4): 509–14. doi:10.1111/j.1365-2559.2007.02794.x. PMID 17711447.
- ↑ 4.0 4.1 Wu X, Petrovic V, Torode IP, Chow CW (2009). "Low grade fibromyxoid sarcoma: problems in the diagnosis and management of a malignant tumour with bland histological appearance". Pathology. 41 (2): 155–60. doi:10.1080/00313020802579276. PMID 19152188.
- ↑ 5.0 5.1 Bartuma H, Möller E, Collin A, Domanski HA, Von Steyern FV, Mandahl N; et al. (2010). "Fusion of the FUS and CREB3L2 genes in a supernumerary ring chromosome in low-grade fibromyxoid sarcoma". Cancer Genet Cytogenet. 199 (2): 143–6. doi:10.1016/j.cancergencyto.2010.02.011. PMID 20471519.
- ↑ Wehrli BM, Weiss SW, Yandow S, Coffin CM (2001). "Gardner-associated fibromas (GAF) in young patients: a distinct fibrous lesion that identifies unsuspected Gardner syndrome and risk for fibromatosis". Am J Surg Pathol. 25 (5): 645–51. PMID 11342777.
- ↑ Coffin CM, Hornick JL, Fletcher CD (2007). "Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases". Am J Surg Pathol. 31 (4): 509–20. doi:10.1097/01.pas.0000213393.57322.c7. PMID 17414097.
- ↑ Swartz RD (2009). "Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment". Am J Kidney Dis. 54 (3): 546–53. doi:10.1053/j.ajkd.2009.04.019. PMID 19515472.
- ↑ Doyle LA, Möller E, Dal Cin P, Fletcher CD, Mertens F, Hornick JL (2011). "MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma". Am J Surg Pathol. 35 (5): 733–41. doi:10.1097/PAS.0b013e318210c268. PMID 21415703.
- ↑ Lee AF, Yip S, Smith AC, Hayes MM, Nielsen TO, O'Connell JX (2011). "Low-grade fibromyxoid sarcoma of the perineum with heterotopic ossification: case report and review of the literature". Hum Pathol. 42 (11): 1804–9. doi:10.1016/j.humpath.2011.01.023. PMID 21658743.
- ↑ Brasanac D, Dzelatovic NS, Stojanovic M (2013). "Giant cystic superficial low-grade fibromyxoid sarcoma". Ann Diagn Pathol. 17 (2): 222–5. doi:10.1016/j.anndiagpath.2011.09.001. PMID 22136982.
- ↑ Vernon SE, Bejarano PA (2006). "Low-grade fibromyxoid sarcoma: a brief review". Arch Pathol Lab Med. 130 (9): 1358–60. doi:10.1043/1543-2165(2006)130[1358:LFSABR]2.0.CO;2. PMID 16948525.
- ↑ Lane KL, Shannon RJ, Weiss SW (1997). "Hyalinizing spindle cell tumor with giant rosettes: a distinctive tumor closely resembling low-grade fibromyxoid sarcoma". Am J Surg Pathol. 21 (12): 1481–8. PMID 9414192.
- ↑ Nielsen GP, Selig MK, O'Connell JX, Keel SB, Dickersin GR, Rosenberg AE (1999). "Hyalinizing spindle cell tumor with giant rosettes: a report of three cases with ultrastructural analysis". Am J Surg Pathol. 23 (10): 1227–32. PMID 10524523.